SERPIND1

Across TCGA pan-cancer cohorts, SERPIND1 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of SERPIND1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SERPIND1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types SERPIND1 is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

HNSC, LUAD, and LSCC are the cancer types where SERPIND1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SERPIND1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	−1.494	<.001	11	view →
LUAD	Female	III,IV	−1.690	<.001	9	view →
LSCC	Male	II,III,IV	−1.580	<.001	9	view →
COAD	Female	All	−1.062	<.001	9	view →
PDAC	Female	All	+0.778	<.001	4	view →
OV	All	All	−1.369	<.001	2	view →
PDAC	Male	IV	−1.680	<.001	1	view →
CCRCC	Male	III,IV	−0.318	.031	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 7 lineages.

SERPIND1–HNSC

Open the HNSC breakdown →